Investor Contacts

Share Registry

Level 12, 680 George Street
Sydney NSW 2000

Locked Bag A14
Sydney South NSW 1235

+61 1300 554 474

Australian Securities Exchange



Level 1, 28 Ord Street
West Perth WA 6005


1232 Hay Street
West Perth WA 6005


11 Mounts Bay Road
Perth WA 6000

ACW Investor Events

Actinogen Medical 2018 Annual General Meeting (AGM)
Wed. 28 Nov 2018 | 11.30am AEST

AGM Chairman’s Address

Managing Director’s AGM Presentation

Video: XanADu, Xanamem & Cortisol: Oct 2018 Barcelona 
Actinogen has achieved a major milestone through enrolling the final patient into XanADu, its landmark trial in Alzheimer’s disease. Find out more on XanADu, and Xanamem and cortisol in Alzheimer’s and other neurological diseases, with commentary from Dr Bill Ketelbey and the Xanamem Clinical Advisory Board.

Results of AGM 

Annual Financial Statements year ended 30 June 2018

Notice of Meeting 

Any questions?
Questions can be submitted via email to

Newsletters and Reports

View More
View More
View More

Frequently Asked Questions

The Company listed on the Australian Securities Exchange in 2007 as Actinogen Limited. In 2014, the Company acquired Corticrine, a company focused on the development of treatment for Alzheimer’s disease. The drug in development by Corticrine was Xanamem. Corticrine received $25m support from the Seeding Drug Discovery program of the Wellcome Trust and the University of Edinburgh and successfully completed a Phase 1 single ascending dose (SAD) study of UE2343 in healthy human volunteers. Corticrine then became part of Actinogen Limited and the company subsequently rebranded to become Actinogen Medical in 2015.

Suite 901, Level 9, 109 Pitt Street, Sydney, NSW 2000

The share registry is managed by Link Market Services. To login and access your holding information, please go to:

The share registry is managed by Link Market Services and shareholders can check their shareholdings by logging into

All company shares are traded on the ASX and can be bought or sold through a licensed stock broker. The process of buying or selling shares is explained on the ASX website, please go to

Non-Australian residents wishing to invest in ACW shares should contact a licensed stock broker which offers cross border transaction services with Australia. Alternatively, online trading platforms offer solutions for overseas investors to invest in international equities. Investors should note that ACW is only listed on the Australian Securities Exchange.

All annual reports are available on our website through this link –    

Current share prices are available on the ASX website and can be searched using the Company’s ASX ticker symbol: ACW. Our Investor Centre also includes the delayed share graph –

The ASX ticker code for the Company is ASX:ACW

The latest financial reports can be found on our website at

Key reporting dates are as follows:

  • 31 July 2018 – Deadline for June Quarter appendix 4C
  • 31 August 2018 – Deadline to report FY18 Financial Results
  • 30 October 2018 – Deadline for September Quarter appendix 4C
  • November 2018 – Annual General Meeting
  • 31 December 2018 – HY 2019 Financial Year end
  • 31 January 2019 – Deadline for December Quarter appendix 4C
  • 28 February 2019 – HY19 Financial Report
  • 30 April 2019 – Deadline for March 2019 quarter appendix 4C
  • 30 June 2019 –Financial Year End

The Company’s end of financial year is the 30th of June

As a listed company Actinogen is required to hold its annual general meeting within five months of its financial year end.  Accordingly, shareholders will be notified in the months of September or October, approximately 28 days in advance of when and where the AGM will be held. Typically, Actinogen holds its AGM towards the end of November.

The Company’s auditors are Ernst and Young

K&L Gates

Peter Webse

Our Corporate Governance policy can be found on our website at: . This includes our Board Charter, Code of Conduct, Continuous Disclosure Policy, Directors Skills Matrix, Diversity Policy, Nomination Committee Charter, Performance Evaluation Practices, Procedures for Selection and Appointment of Directors, Remuneration Committee Charter, Risk Management and Internal Compliance and Control, the Securities Trading Policy and Shareholders Communication Policy.

The Company does not currently have a dividend policy as the Company is not yet revenue generating. The Board reviews its growth strategy at regular intervals and assesses its against the Company’s working capital requirements and growth opportunities. Until the Company is generating returns, it is not expected to implement a dividend policy.

Codes and Guidelines

AusBiotech has made available reports designed to assist corporate governance in the sector.

  • The Code of Best Practice for Reporting Life Sciences Companies (the Code)
  • The Guide for Life Science Company Directors (the Guide)
  • Corporate Governance in the ASX-listed Life Sciences Sector